reports
EQS-News: Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlag...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlage - J.POD® Toulouse, France (EU) 20.09.2024 / 15:29 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. J.POD® Toulouse, France (EU) bringt disruptive, skalierbare, kontinuierliche Biologika-Herstellungstechnologie in die Region Just – Evotec Biologics J.POD®-Technologie bietet einen Paradigmenwechsel in der Bioproduktion mit kosteneffizienten und flexiblen Lösungen für die klinische und kommerzielle Versorgung ...
EQS-News: Just – Evotec Biologics opens cutting-edge biologics facilit...
EQS-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU) 20.09.2024 / 15:29 CET/CEST The issuer is solely responsible for the content of this announcement. J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions Hamburg, Germany, and Toulouse, Franc...
Evotec SE: 1 director
A director at Evotec SE bought 10,000 shares at 6.109EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- Olfa Taamallah
- Yan Derocles
- Olfa Taamallah
- Yan Derocles
- Robert Jan Vos
B&S Group S.A. : We reiterate our Outperform, mainly on valuation
>Solid operational results show B&S Group is on track for its goals in 2024 - Following B&S Group’s H1 2024 results (19 August), we now put through some changes in our model. As a reminder, the group’s H1 2024 results were slightly better than our forecasts. Organic sales growth came in at 4.2% (ABNe: 2.6%) in H1 2024. The Personal Care and Food divisions outperformed our revenue expectations. On divisional EBITDA, we conclude that Personal Care reported strongly, an...
- Oliver Metzger
- Sinan Doganli
ODDO : First feedback – DAY 1
We host the 15th edition of the Corporate Conference in cooperation with Commerzbank on September 3rd & 4th 2024 in Frankfurt am Main. This year we are welcoming 90 German small, mid and large cap companies. - >Adidas (+) – On trackAixtron (=) – No short-term inflection, but high confidence in long-term prospectsAllgeier (+) – Is confident it can achieve 15% EBITDA margin by the end of 2025 ams OSRAM (=) – Some cautiousness on auto/industrial, still co...
FME FRESENIUS MEDICAL CARE AG
CEC CECONOMY AG
AMS AMS AG
ADS ADIDAS AG
CBK COMMERZBANK AG
EVT EVOTEC SE
GBF BILFINGER SE
BOSS HUGO BOSS AG
SDF K+S AG
TPE PVA TEPLA AG
ZAL ZALANDO SE
BAS BASF SE
AIXA AIXTRON SE
BC8 BECHTLE AG
SAX STROEER SE & CO. KGAA
LEG LEG IMMOBILIEN AG
WAF SILTRONIC AG
BNR BRENNTAG SE
SMHN SUESS MICROTEC AG
HBH HORNBACH HOLDING AG & CO. KGAA
FNTN FREENET AG
AEIN ALLGEIER HOLDING AG
IOS IONOS GROUP SE
EQS-News: Evotec gibt Veränderung im Vorstand bekannt
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec gibt Veränderung im Vorstand bekannt 03.09.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dr. Matthias Evers tritt mit Wirkung zum 01. Oktober 2024 als Chief Business Officer zurück Verantwortlichkeiten werden auf andere Vorstandsressorts verteilt Hamburg, 03. September 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, dass ihr Chief Business Officer, Dr. Matthias Evers entschieden...
EQS-News: Evotec announces change in Management Board
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces change in Management Board 03.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions Hamburg, Germany, 03 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to s...
- Roy Külter
- Steven Boumans
- Roy Külter
- Steven Boumans
- Sinan Doganli
Allgeier SE : Revised guidance still seems ambitious, despite a more p...
>Reduction of low margin staffing business leads to gross margin improvement - Following Allgeier’s Q2 release, we update our outdated model and reassess our assumptions. Allgeier is in an ongoing transformation process in which the company is substantially reducing the low margin part of its staffing business (Enterprise IT segment). This process has already started in H2 2023 and is starting to bear fruit with gross profit margins expanding from roughly 68.2% in H1 ...
- Marc Zwartsenburg
- CEFA
- Tijs Hollestelle
B&S Group/Keep going/BUY
B&S reported solid interim results, with revenue and EBITDA slightly ahead of our and consensus expectations and net profit somewhat lower than expected due to higher finance costs. Several key divisions continued to grow strongly in 1H24 and posted healthy operating margins, underscoring B&S' ability to deal with cost inflation. Performance of the Liquor unit remained poor, with no signs of a recovery in 2Q24. But B&S has taken additional measures to improve efficiency and lower costs. Inventor...
- ING Helpdesk
- Robert Jan Vos
B&S Group S.A. : Sales and EBITDA solid; financial leverage/working ca...
>Decent sales and EBITDA performance, but financial leverage high in H1 2024 - B&S Group reported organic sales growth of 4.2% and sales of € 1,102.1m in H1 2024 (ABNe: 2.6% and € 1,085m). Gross profit amounted to € 166m, or a gross profit margin of 15.1% (ABNe: € 169.5m and 15.6%). Group EBITDA came in at € 52.7m, implying EBITDA profitability of 4.8% (ABNe: € 50.6m and 4.7%). Net profit to equity holders was € 13.2m, or slightly below our forecast of € 14.5m. Net de...
- Klaus Ringel
- Michael Foundoukidis
- Klaus Ringel
- Michael Foundoukidis
- Oliver Metzger
- Stephan Wulf
Evotec SE : H1 even weaker than expected – cash burn less alarming tha...
>H1 results below already cautious expectations - Evotec’s H1 results came in below already cautious expectations. H1 2024 sales of € 391m (+1.5%) were 1% below our (€ 393m) and 5% below the consensus estimates (€ 412m). The group’s gross profit of € 51m (-49%) is 18% below our estimates and 21% below the consensus. Adj. EBITDA came in at a loss of -€ 0.5m (vs € 26m in H1 2023), which compares to our estimate of € 9m and the consensus of € 12m.Just Evotec Biologi...
- Bruno Bulic
Evotec in restructuring mode
Evotec today presented additional details on the restructuring plan on the back of the weakness in Discovery business (Shared R&D) aimed at delivering EUR 40mn annual savings from H2 2024. Evotec intends to cut 400 positions, close the operation of Halle/Westphalia, Germany, in addition to exit
EQS-News: Evotec SE gibt Ergebnisse für H1 2024 bekannt: Herausfordern...
EQS-News: Evotec SE / Schlagwort(e): Halbjahresergebnis Evotec SE gibt Ergebnisse für H1 2024 bekannt: Herausforderndes Jahr; Neuausrichtung für nachhaltiges profitables Wachstum aufbauend auf Kernkompetenzen gewinnt an Dynamik 14.08.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Weicher Markt für Shared R&D Dienstleistungen; Umsatz geht im ersten Halbjahr 2024 im Vergleich zum Vorjahr um 7 % zurück. Anhaltendes Wachstum des Auftragsbestands im Bereich Discovery – höherer Anteil integrierter langfristiger Verträg...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.